Modulation of Angiotensin II–HIF-1α-HILPDA Signaling and NPC Radioresistance

Study Background and Research Question

Nasopharyngeal carcinoma (NPC) is an epithelial malignancy predominantly affecting populations in East and Southeast Asia. While radiotherapy is the primary treatment due to NPC’s anatomical inaccessibility for surgery, radioresistance remains a major clinical hurdle, contributing to local recurrence in approximately 20% of patients. Understanding the molecular factors that drive this resistance is essential for optimizing therapeutic strategies. The renin-angiotensin system (RAS), beyond its classic roles in cardiovascular regulation, has recently gained attention for its local actions in the tumor microenvironment, particularly through angiotensin II (Ang II) signaling. The reference study (Chengcong Chen et al., 2025) addresses the critical question: How does local Ang II modulate NPC radioresistance, and can its downstream effectors provide new targets for radiosensitization?

Key Innovation from the Reference Study

The central innovation lies in the elucidation of a positive feedback axis involving local Ang II, hypoxia-inducible factor-1 alpha (HIF-1α), and hypoxia-inducible lipid droplet-associated protein (HILPDA). Specifically, the study demonstrates that local Ang II promotes radioresistance in NPC by suppressing ferroptosis—a regulated cell death pathway dependent on iron and lipid peroxidation—through transcriptional upregulation of HILPDA via HIF-1α. This mechanistic insight identifies the Ang II–HIF-1α–HILPDA axis as a promising therapeutic target for overcoming NPC radioresistance.

Methods and Experimental Design Insights

The investigators established radioresistant NPC cell lines (HONE1-RR and SUNE1-RR) to model acquired resistance. Key molecular endpoints were interrogated using quantitative reverse transcription PCR (qRT-PCR), western blotting, and ELISA to quantify the activation of angiotensinogen (AGT) and local Ang II. The extent of ferroptosis following irradiation was assessed via transmission electron microscopy, ferrous ion quantification, and lipid oxidation assays. To dissect signaling pathways, the study employed bioinformatics analysis, co-immunoprecipitation, and dual-luciferase reporter assays to confirm interactions and transcriptional regulation. Functional assays included colony formation, Cell Counting Kit-8 (CCK8) cell viability, and in vivo evaluation using a nude mouse xenograft model. Immunohistochemistry was performed on clinical NPC tissues to correlate AGT, HIF-1α, HILPDA, and GPX4 expression with patient prognosis and radiosensitivity.

Protocol Parameters

• Radioresistant cell line establishment: HONE1-RR and SUNE1-RR generated via repeated irradiation cycles; suitable for modeling acquired radioresistance.
• Ferroptosis assessment: Lipid oxidation and ferrous ion quantification performed post-irradiation to assess cell death modality.
• In vivo radiosensitivity testing: NPC xenografts in immunodeficient mice; therapeutic interventions administered intraperitoneally.
• Molecular target analysis: Immunohistochemistry on NPC tissue microarrays to examine AGT, HIF-1α, HILPDA, and GPX4 expression correlation with clinical outcomes.
• Pharmacological inhibition workflow: Ang II receptor antagonists and ferroptosis inducers co-administered to evaluate combined effect on radiosensitivity.

Core Findings and Why They Matter

Several key discoveries emerged from the study:

• Local Ang II Drives Radioresistance: Elevated local Ang II in NPC cells and tissues establishes a positive feedback loop with HIF-1α, both by stabilizing HIF-1α via MAPK pathway activation and through direct binding by AGT, limiting HIF-1α degradation (reference study).
• Suppression of Ferroptosis: This axis promotes expression of HILPDA, enhancing lipid droplet accumulation and repressing ferroptosis, as indicated by reduced lipid peroxidation markers and iron accumulation in resistant cells.
• Clinical Correlation: High expression of AGT, HIF-1α, and HILPDA in patient samples correlates with poor prognosis and reduced radiosensitivity.
• Therapeutic Modulation: Combined treatment with Ang II receptor blockers and ferroptosis inducers significantly increased radiosensitivity in both cell-based and xenograft models, suggesting dual targeting as a promising radiosensitization strategy.

These findings collectively highlight the AGT–HIF-1α–HILPDA axis as a central regulator of NPC radioresistance, offering actionable biomarkers and therapeutic targets for future translational research.

Comparison with Existing Internal Articles

The internal articles provide complementary perspectives on the same mechanistic axis. For example, "Angiotensin II Suppresses Ferroptosis to Drive NPC Radioresistance" and "Angiotensin II–HIF-1α-HILPDA Axis Drives Radioresistance in NPC" both reinforce the role of local Ang II in promoting radioresistance via ferroptosis suppression. These resources echo the reference study’s conclusion that dual targeting of Ang II signaling and ferroptosis could enhance radiotherapy outcomes. The internal summaries also draw attention to the utility of AGT, HIF-1α, and HILPDA as biomarkers for prognosis and treatment stratification, thus supporting the translational relevance of the reference findings.

Limitations and Transferability

Despite the robust mechanistic delineation, several limitations should be considered. The models primarily rely on established cell lines and xenografts, which, while informative, may not fully capture the heterogeneity of human NPC tumors or the complexity of the tumor microenvironment. Additionally, the clinical efficacy and safety of combined Ang II blockade and ferroptosis induction require further validation in prospective trials. Transferability to other tumor types or microenvironments remains an open question, as the AGT–HIF-1α–HILPDA axis may exhibit differential regulation in non-NPC contexts.

Research Support Resources

For researchers investigating MAPK/ERK pathway inhibition or modeling kinase-driven tumor resistance mechanisms, selective ERK1/2 inhibitors such as SCH772984 (SKU A3805, APExBIO) can be integrated into workflows to dissect ERK-dependent signaling events. As an ATP-competitive ERK1/2 inhibitor, SCH772984 offers high selectivity and nanomolar potency, and has been used in studies of BRAF, NRAS, and KRAS mutant tumor inhibition and pancreatic cancer xenograft models according to the product information. Proper solubilization protocols and storage conditions should be followed for best experimental outcomes. Further, combining such pathway inhibitors with radiation or ferroptosis inducers may enable advanced interrogation of resistance mechanisms in NPC and related malignancies.